"10.1371_journal.pone.0123626","plos one","2015-04-23T00:00:00Z","Philippe Gagnon; Richard Casaburi; Didier Saey; Janos Porszasz; Steeve Provencher; Julie Milot; Jean Bourbeau; Denis E O’Donnell; François Maltais","Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America; Respiratory Epidemiology and Clinical Research Unit, Montréal Chest Institute, McGill University, Montréal, Québec, Canada; Queen’s University and Kingston General Hospital, Kingston, Ontario, Canada","Conceived and designed the experiments: PG RC DS JP DEO FM. Performed the experiments: PG RC DS JP SP JM JB DEO FM. Analyzed the data: PG RC DS FM. Contributed reagents/materials/analysis tools: PG RC DEO FM. Wrote the paper: PG RC DS JP SP JM JB DEO FM.","The authors of this manuscript have the following competing interests: PG declares that he has no competing interests. RC is a consultant for Boehringer Ingelheim, Forest and Novartis. He has served on advisory boards for Boehringer Ingelheim and Forest, and has received payment for lectures including service on speakers’ bureaus from AstraZeneca, Boehringer Ingelheim, Forest, Novartis and Pfizer. He has received payment for development of educational presentations from Boehringer Ingelheim. His institution has received grants from Boehringer Ingelheim, Forest, GlaxoSmithKline and Novartis. DS declares that he has no competing interests. JP reports grants from Boehringer Ingelheim, Inc., personal fees from Boehringer Ingelheim, Inc., non-financial support from Boehringer Ingelheim, Inc., personal fees from Actelion, during the conduct of the study. In addition, he has a patent US 7,628,732 and a patent US 7,927,251 issued. SP is a clinician scientist of the Fonds de la Recherche en Santé du Québec. He has served on advisory boards for Actelion, Eli Lilly, GlaxoSmithKline and Pfizer and has received payment for lectures from Actelion and Eli Lilly. His institution has received grants from Actelion, Bayer and GlaxoSmithKline. JM is a clinician scientist of the Fonds de la Recherche en Santé du Québec and declares that she has no competing interests. JB is a recipient of a CIHR/Rx&D Collaborative Research Program Operating Grants (# 93326) for The Canadian Cohort of Obstructive Lung Disease (CanCOLD). He received research funding via the Research Institute of the McGill University Health Centre, from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer and Theratechnologies; and has served on speakers, consultation panels and/or advisory boards for the above listed pharmaceutical companies. DEO has served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Roche. He has received payment for lectures including service on speakers’ bureaus from Boehringer Ingelheim, GlaxoSmithKline and Pfizer. His institution has received grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed and Pfizer. FM holds a GSK/CIHR Research Chair on COPD at Université Laval. He is a consultant for Boehringer Ingelheim. He has served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline and Pfizer and has received payment for lectures including service on speakers bureaus from Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer. His institution has received grants from Boehringer Ingelheim and GlaxoSmithKline. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","04","Philippe Gagnon","PG",9,FALSE,6,9,4,9,TRUE,TRUE,FALSE,0,NA,FALSE
